Spero Therapeutics Revenue
Biotechnology Research • 
Cambridge, Massachusetts, United States • 21-50 Employees
Spero Therapeutics revenue & valuation
| Annual revenue | $48,600,000 |
| Revenue per employee | $1,012,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $155,500,000 |
| Total funding | $9,000,000 |
Key Contacts at Spero Therapeutics
Shekman Wong
Executive Director, Head Of Clinical Pharmacology, Dmpk And Drug Analysis
Shai Biran
Senior Director Investor Relations
Sath Shukla
Member Of The Board Of Directors
Brian Kane
Senior Director, Program Lead
Katie Mcclure
Associate Director, Fp&A
Peter Castrichini
Associate Director, Assistant Controller
Myriah Satterfield
Director, Clinical Data Management
Sarah Pileeki
Associate Director Quality Control
Sarah Grayson Moore
Associate Director Clinical Operations
Nivedita Bhatt
Executive Director
Company overview
| Headquarters | 675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US |
| Phone number | +18572421600 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Antibacterial Therapies, Novel Therapeutics, Infectious Disease |
| Founded | 2013 |
| Employees | 21-50 |
| Socials |
Spero Therapeutics Email Formats
Spero Therapeutics uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@sperotherapeutics.com), used 82.4% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@sperotherapeutics.com | 82.4% |
{first initial} | j@sperotherapeutics.com | 5.9% |
{last name}{last name} | doedoe@sperotherapeutics.com | 5.9% |
{f2}{last name} | {f2}doe@sperotherapeutics.com | 2.9% |
{first name}{last name} | johndoe@sperotherapeutics.com | 2.9% |
About Spero Therapeutics
We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant ("MDR”) bacterial infections with high unmet need. Our pipeline consists of three mid to late-stage clinical assets. Tebipenem HBr is in Phase 3 development, with the potential to be the first broad-spectrum oral carbapenem to treat complicated urinary tract infections ("cUTIs”) including acute pyelonephritis, caused by certain microorganisms, in adult patients. SPR206 is a Phase 2 ready IV-administered antibiotic being developed as an innovative option to treat MDR Gram-negative bacterial infections in the hospital setting. SPR720, the development of which was recently suspended, is a Phase 2 investigational oral agent for the first-line treatment of nontuberculous mycobacterial ("NTM”) pulmonary disease, a rare disease. As previously disclosed, following the SPR720 program suspension, we are evaluating other potential paths forward as the remaining data are collected and analyzed.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Spero Therapeutics has 23 employees across 9 departments.
Departments
Number of employees
Spero Therapeutics Tech Stack
Discover the technologies and tools that power Spero Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Issue trackers
CDN
JavaScript libraries
Analytics
Webmail
Miscellaneous
Security
Page builders
Analytics
Analytics
CDN
Canada
France
United Kingdom
Australia
Frequently asked questions
4.8
40,000 users
